Serum lipids associated with inflammation-related PET-FDG uptake in symptomatic carotid plaque

Neurology

Volumn 82, Issue 19, 2014, Pages 1693-1699

  Chróinín, Danielle Ní ^a   Marnane, Michael ^a   Akijian, Layan ^a   Merwick, Áine ^a   Fallon, Emer ^a   Horgan, Gillian ^a   Dolan, Eamon ^b   Murphy, Sean ^a   O'Rourke, Killian ^a   O'Malley, Kevin ^a   O'Donohoe, Martin ^a   McDonnell, Ciaran ^a   Noone, Imelda ^c   Barry, Mary ^c   Crowe, Morgan ^c   Kavanagh, Eoin ^a   O'Connell, Martin ^a   Kelly, Peter J ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b Stroke and Hypertension Unit   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUORODEOXYGLUCOSE F 18; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPOTHESIS; IMAGE ANALYSIS; INFLAMMATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CAROTID STENOSIS; CHOLESTEROL; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; FUNCTIONAL NEUROIMAGING; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TRIGLYCERIDES;

EID: 84902151359     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000408     Document Type: Article

References (31)

1. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002;106:3143-3421.
2. Rothwell PM, Coull AJ, Giles MF, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363:1925-1933.
3. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010;304:1350-1357.
4. Marnane M, Merwick Á, Sheehan ÓC, et al. Carotid plaque inflammation on 18F-Fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol 2012;71:709-718.
5. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-1362.
6. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005;111:1543-1550.
7. Tardif JC, Grégoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-1682.
8. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008;103: 1084-1091.
9. Rajamäki K, Lappalainen J, O{double acute}o{double acute}rni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5:e11765.
10. Abela GS, Aziz K. Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events-a novel insight into plaque rupture by scanning electron microscopy. Scanning 2006;28:1-10.
11. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008;49:871-878.
12. Tahara N, Kai H, Nakaura H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J 2007;28:2243-2248.
13. 18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol 2007;49:1533-1539.
14. 18F-FDG-PET. J Nucl Med 2011;52:10-17.
15. 18F-fluorodeoxyglucose positron emission tomography. J Clin Endocrinol Metab 2011;96:E488-492.
16. Lee SJ, On YK, Lee EJ, Choi JY, Kim B-T, Lee K-H. Reversal of vascular 18F-FDG uptake with plasma highdensity lipoprotein elevation by atherogenic risk reduction. J Nucl Med 2008;49:1277-1282.
17. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-1831.
18. Rudd JHF, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers. Circ Cardiovasc Imaging 2009; 2:107-115.
19. Bucerius J, Duivenvoorden R, Mani V, et al. Prevalence and risk factors of carotid wall inflammation in coronary artery disease patients. FDG-PET and CT imaging study. JACC Cardiovasc Imaging 2011;4:1195-1205.
20. Saito H, Kuroda S, Hirata K, et al. Validity of dual MRI and F-FDG PET imaging in predicting vulnerable and inflamed carotid plaque. Cerebrovasc Dis 2013;35:370-377.
21. Izquierdo-Garcia D, Davies JR, Graves MJ, et al. Comparison of methods for magnetic resonance-guided [18-F] fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methods. Stroke 2009; 40:86-93.
22. NASCET Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis: the North American Symptomatic Carotid Endarterectomy Trial Collaborators. New Eng J Med 1991;325:445-453.
23. Tawakol A, Fayad ZA, Mogg R, et al. High dose statin results in a further reduction in atherosclerotic inflammation compared with low dose statin: results of a Multi-Center PET-CT Study. Circulation 2011;124:A18242.
24. Aikawa M, Libby P. Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma. Ann N Y Acad Sci 2000;902:140-152.
25. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731-1737.
26. Redgrave JN, Lovett JK, Rothwell PM. Histological features of symptomatic carotid plaques in relation to age and smoking: the oxford plaque study. Stroke 2010; 41:2288-2294.
27. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008;359: 2195-2207.
28. Merwick Á, Albers GW, Arsava EM, et al. Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment. Stroke Epub 2013 Aug 1.
29. Van Leuven SI, van Wijk DF, Volger OL, et al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 2010;211:231-236.
30. Ridker P. Cardiovascular inflammation reduction trial. Available at: http://clinicaltrials.gov/ct2/show/NCT01594333. Accessed April 6, 2013.
31. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Antiinflammatory Thrombosis Outcomes Study. Am Heart J 2011;162:597-605.